Last reviewed 2026-04-22 · How we verify

optimized ibuprofen

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Fever, Inflammation associated with arthritis and musculoskeletal conditions.

At a glance

Mechanism of action

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively blocks COX-1 and COX-2 enzymes, which catalyze prostaglandin production. By reducing prostaglandins, it suppresses inflammatory responses and pain signaling. The term 'optimized' likely refers to formulation improvements (e.g., faster absorption, improved bioavailability, or reduced GI irritation) rather than a novel mechanism.

Approved indications

• Mild to moderate pain
• Fever
• Inflammation associated with arthritis and musculoskeletal conditions

Common side effects

• Gastrointestinal upset (dyspepsia, nausea)
• Abdominal pain
• Headache
• Dizziness
• Increased cardiovascular risk (with chronic use)
• Renal impairment (with chronic use)

Key clinical trials

• ERAS Program Implementation for MIPD (NA)
• Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis (PHASE2)
• Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• optimized ibuprofen CI brief — competitive landscape report
• optimized ibuprofen updates RSS · CI watch RSS
• OSF Healthcare System portfolio CI